Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Scientists at Texas A&M University have found evidence suggesting that there may be a link between Alzheimer's disease risk and type 2 diabetes. This is backed by data from a separate study, which found that roughly 81% of individuals living with Alzheimer's disease also have type 2 diabetes. Alzheimer's is a progressive brain disorder that affects memory, thinking and behavior. The disorder is also a common cause of dementia, accounting for at least 60% of dementia cases. For patients that have already been diagnosed with Alzheimer's disease, hope lies in companies  such as Longeveron Inc. (NASDAQ: LGVN) that are working round the clock to develop effective treatments which can halt the progression of this progressive condition.

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Wednesday's trading session at $3.11, up 804.8589%, on 124,192 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.92/$44.00.

Recent News

• Longeveron Inc. (NASDAQ: LGVN) - Researchers Link Type 2 Diabetes to Heightened Alzheimer's Risk
• InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split
• Study Links Parkinson's Onset in Rocky Mountain Area to Agricultural Pesticides

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

A report outlining the state of Environmental, Social & Governance ("ESG") investing in private markets has suggested that a phenomenon called "greenhushing'" is causing some asset managers to retreat from their public environment, social, and governance reporting commitments. Greenhushing refers to the practice of retaining information on climate-change mitigation strategies due to the fear that releasing this information could potentially risk a company's reputation. Companies will either do this through avoidance or outright refusal to divulge any climate-action-related information, meaning they won't provide any information if nobody asks and will decline to answer any queries that they do receive. It remains to be seen whether the growing trend of greenhushing will fizzle out and companies that already embrace ESG principles, such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), will keep strengthening their implementation of those principles.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Wednesday's trading session at $0.064, off by 13.5135%, on 158,540 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.047785/$0.154.

Recent News

• First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) - Greenhushing' Is Adversely Impacting ESG Activity in Private Markets
• How Geopolitical Shifts Could Impact Net-Zero Ambitions, Energy Sovereignty
• BlackRock Reports Increasing Politicization of ESG Poses Business Risks

Vision Marine Technologies Inc. (NASDAQ: VMAR)

The QualityStocks Daily Newsletter would like to spotlight Vision Marine Technologies Inc. (NASDAQ: VMAR).

The burgeoning renewable energy industry is using retired electric vehicle batteries to revolutionize green-energy storage. With millions of aging electric vehicles set to retire their batteries over the next decade, the electric-vehicle industry was looking at a potential avalanche of e-waste from old EV batteries. These batteries could leach harmful chemicals and metals into the environment and undo many of the environmental benefits of transitioning to electric vehicles. However, green-energy storage facilities are taking advantage of retired EV batteries to kill two birds with one stone: provide a means of storing clean energy while limiting environmental pollution by giving old electric vehicle batteries a new lease on life. This would require communication and cooperation between energy companies, regulators and technology companies to foster an environment of collaborative innovation that espouses ecofriendly values. Individual companies such as Vision Marine Technologies Inc. (NASDAQ: VMAR) can also play a significant role by taking the lead in transforming energy use within the industries in which they operate.

Vision Marine Technologies Inc. (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion™ 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

Vision Marine Technologies Inc. (NASDAQ: VMAR), closed Wednesday's trading session at $0.6, up 0.016669%, on 26,269 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.57/$5.60.

Recent News

• Vision Marine Technologies Inc. (NASDAQ: VMAR) - Retired Electric Vehicle Batteries Are Revolutionizing Green-Energy Storage
• Vision Marine Technologies Inc. (NASDAQ: VMAR) Helps Lead the Electric Boating Revolution, Establishes Partnership with Key Distributor
• Vision Marine Technologies Inc. (NASDAQ: VMAR) Unveils New E-Boat Model, Names New CFO in Preparation for Industry Growth

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a leading entity in the cannabis and agricultural technology sectors, today announced remarkable advancements across its operations. MedCana is poised for significant growth and profitability with its subsidiaries in the final stages of negotiations to determine varietals to export to Europe and Australia, and Eko2o S.A.S. rapidly expanding its reach within the agricultural industry. MedCana's strategic foray into cannabis production is nearing fruition, with operations gearing up to meet the stringent quality and regulatory standards of the European and Australian markets. In addition, Eko2o S.A.S., a majority-controlled subsidiary of MedCana, is making notable strides in distributing advanced greenhouse and irrigation technologies to large producers of flowers, avocados and bananas. "We are delighted with the progress we've made across all fronts. The final negotiations for cannabis exportation and the rapid expansion of Eko2o's technology distribution mark a significant milestone in our journey," said Jose Gabriel Diaz, CEO of SFWJ/MedCana. "We are now closer than ever to achieving profitability and solidifying our position as industry leaders."

To view the full press release, visit https://ibn.fm/0KO34

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Wednesday's trading session at $0.0499, even for the day, on 2 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

• Software Effective Solutions Corp. (OTC: SFWJ) - InvestorNewsBreaks - Software Effective Solutions Corp. (OTC:SFWJ) Marks Significant Progress Across Its Diverse Portfolio
• Software Effective Solutions Corp. (SFWJ) Completes Key Acquisitions, Is Committed to Becoming Cannabis Market Leader
• InvestorNewsBreaks - Software Effective Solutions Corp.'s (SFWJ) Eko2o S.A.S Eyes Expansion into Costa Rica and Central America

SuperCom Ltd. (NASDAQ: SPCB)

The QualityStocks Daily Newsletter would like to spotlight SuperCom Ltd. (NASDAQ: SPCB) .

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, IoT and cybersecurity sectors, has announced that its fully owned subsidiary, Leaders in Community Alternatives ("LCA"), has won a new project in California, valued at up to $2 million. As part of the project, LCA will provide a comprehensive jail-based program focusing on re-entry services for adult inmates, designed to support individuals transitioning back into the community. "This award marks an exciting expansion to a new county for SuperCom and underscores our unwavering commitment to enhancing public safety in new territories. This achievement reflects our proven expertise in delivering critical re-entry services and our dedication to positively impacting lives and communities," said Ordan Trabelsi, president and CEO of SuperCom. "This collaboration with a local behavioral health provider in the project's county is a testament to our ability to forge meaningful partnerships that amplify our impact. It is through these collaborative efforts that we can bring our proprietary services and technology to new heights, reinforcing our mission to offer comprehensive solutions that address complex challenges faced by government customers and the communities they serve."

To view the full press release, visit https://ibn.fm/tILK1

SuperCom Ltd. (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary Puresecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (AI) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

• Long Battery Life (No Tag Charging Required)
• Ultra Lightweight Form Factor
• Next-Gen Location Tech
• Protection of Domestic Violence Victims
• And More

 

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

SuperCom Ltd. (NASDAQ: SPCB), closed Wednesday's trading session at $0.178, off by 4.0431%, on 1,628,163 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1524/$1.6399.

Recent News

• SuperCom Ltd. (NASDAQ: SPCB) - InvestorNewsBreaks - SuperCom Ltd. (NASDAQ: SPCB) Awarded New California-Based Project Valued at up to $2M
• TechMediaBreaks - SuperCom Ltd. (NASDAQ: SPCB) Continues to Adapt to Market Needs, Deliver Cutting-Edge Technology
• SuperCom Ltd. (NASDAQ: SPCB) Offers Superior Electronic Monitoring Solutions, as Demand for Public Safety and Alternatives to Incarceration Grows

Sigyn Therapeutics Inc. (OTCQB: SIGY)

The QualityStocks Daily Newsletter would like to spotlightFathom Sigyn Therapeutics Inc. (OTCQB: SIGY).

Sigyn Therapeutics (OTCQB: SIGY), a medical technology company, is developing blood purification technologies to treat life-threatening conditions that are not addressed with current market-cleared drug agents as well as an expansive pipeline of technologies to optimize the benefit of cancer therapies. "The company's lead product candidate, Sigyn Therapy(TM), is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy (‘CRRT') machines already installed in hospitals and clinics. The device incorporates a formulation of adsorbent components to optimize the broad-spectrum reduction of viral pathogens, bacterial toxins and inflammatory mediators from the bloodstream," a recent article reads. "The company is also deploying novel strategies to enhance the performance of cancer therapies. In this regard, ChemoPrep(TM) is designed to optimize the delivery of chemotherapy, the most commonly administered cancer drug, while ImmunePrep(TM) is designed to enhance the benefit of immunotherapeutic antibodies, which account for nine of the top 15 selling cancer drugs… ‘We don't make the drugs; we make the drugs perform better,' said James A. Joyce, Sigyn Therapeutics' co-founder, chairman and CEO."

To view the full article, visit https://ibn.fm/5RmZq

Sigyn Therapeutics Inc. (OTCQB: SIGY) is a development-stage medical technology company headquartered in San Diego, California. The company’s therapeutic candidates include Sigyn Therapy™ to address pathogen-associated inflammatory disorders, the ImmunePrep™ platform to enhance the performance of immunotherapeutic antibodies, ChemoPrep™ to improve the delivery of cancer chemotherapy and ChemoPure™ to reduce the toxicity of chemotherapy.

Sigyn created each of these technologies with two prerequisites in mind: 1) they must offer to overcome a clearly defined limitation in healthcare, and 2) their successful clinical advancement would offer a potential competitive advantage to established therapeutic organizations.

Sigyn Therapy™

The company is advancing Sigyn Therapy™ to treat pathogen-associated inflammatory disorders that are not addressed with FDA approved drugs. Candidate treatment indications include community-acquired pneumonia, drug-resistant virus and bacterial infections, endotoxemia and sepsis, which is the leading cause of hospital deaths in the United States.

The technology has the following attributes and capabilities.

• Sigyn Therapy™ incorporates a formulation of adsorbent components that have more than 200,000 square meters (~50 acres) of surface area on which to adsorb and remove therapeutic targets from the bloodstream.
• In vitro studies have demonstrated the ability of Sigyn Therapy™ to eliminate life-threatening pathogen and inflammatory disease targets from human blood plasma. In these studies, 12 relevant targets, including viral pathogens, bacterial toxins and inflammatory cytokines, were validated. Subsequent animal studies were completed at the University of Michigan.
• Sigyn Therapy™ is highly efficient, as the entire circulatory system of a patient can pass through the device ~15-times during a four-hour treatment.
• To allow for broad deployment, Sigyn Therapy™ is designed for use on the established infrastructure of dialysis and continuous renal replacement machines already located in hospitals and clinics around the world.

First-in-human studies of Sigyn Therapy™ plan to enroll dialysis dependent end-stage renal disease (ESRD) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. There are more than 550,000 individuals with ESRD in the United States, which result in approximately 85 million dialysis treatments being administered each year.

The ImmunePrep™ Platform

Immunotherapeutic antibodies to treat cancer are among the most valued assets in global medicine. However, these drugs suffer from a severe limitation: they are poorly delivered to cancer cell targets, and, as a result, a majority of patients do not respond to therapy.

The Sigyn team recognized that just a small fraction of an antibody dose reaches its cancer cell target, yet a significant portion of the same dose can be sequestered by circulating decoys that display the target (antigen) binding site of the antibody. In response, Sigyn designed the ImmunePrep™ platform to leverage the use of therapeutic antibodies to create extracorporeal blood purification devices that sweep antibody decoys from the bloodstream prior to the subsequent infusion (normal delivery) of the same therapeutic antibody.

The company believes its reverse decoy mechanism will increase the availability of antibodies to interact with their intended disease targets, and, simultaneously, the devices will also extract disease targets from the bloodstream to further improve patient benefit.

The opportunity to enhance the performance of therapeutic antibodies is significant. Consider that Pfizer’s $43 billion acquisition of Seagen Inc. and Amgen’s $27.8 billion acquisition of Horizon Therapeutics were the highest valued M&A deals of 2023. In both cases, transaction values were driven by market-cleared antibody assets.

Perhaps more revealing were the values placed on clinical-stage (pre-revenue) therapeutic antibody candidates. In this regard, consider Merck’s $10.8 billion acquisition of Prometheus Biosciences and Roche’s $7 billion acquisition of a clinical-stage antibody from Roivant Sciences.

In the backdrop of these M&A transactions, the immune checkpoint antibody Keytruda (Merck) became the world’s best-selling (non-vaccine) drug in 2023, with anticipated revenues of ~$24 billion.

ChemoPrep™ and ChemoPure™

Recent scientific publications have reported that only 1% of chemotherapy is delivered to the tumor cell targets of cancer patients. In response, the Sigyn team designed ChemoPrep™ to overcome a delivery limitation of the most commonly administered drug to treat cancer.

The company is developing ChemoPrep™ to reduce the circulating presence of tumor-derived exosomes (tumor exosomes), which interfere with chemotherapy delivery. High concentrations of tumor exosomes in the bloodstream correspond with poor treatment outcomes, whereas low concentrations of tumor exosomes correspond with more favorable outcomes. As compared to non-cancer subjects, exosome populations are reported to be 10x to 500x higher in the bloodstream of cancer patients. Based on these factors, the company believes there is a compelling scientific rationale to reduce the circulating presence of tumor exosomes prior to chemotherapy administration.

Inversely, the Sigyn team recognized that if 99% of chemotherapy was missing its target, then there was a need to eliminate off-target chemotherapy from the bloodstream to reduce toxicity and limit organ damage. This factor led to the design of ChemoPure™ to reduce treatment toxicity by reducing the presence of off-target chemotherapy from the bloodstream. The company believes that a reduction in chemotoxicity may also alleviate treatment-related fatigue and potentially temper the long-term health consequences associated with chemotherapy administration.

Management Team

James A. Joyce is Co-Founder, Chairman and CEO of Sigyn Therapeutics. He has more than two decades of public company CEO and corporate board leadership experience and is an inventor or co-inventor of 20 pending or issued patents, including those underlying ImmunePrep, ChemoPrep, ChemoPure and Sigyn Therapy. Previously, he was founder and CEO of Aethlon Medical, a therapeutic technology company that he built from a start-up to a Nasdaq-traded company. Under his leadership, Aethlon developed the first medical device to receive two breakthrough device designations from the FDA. Mr. Joyce graduated from the University of Maryland.

Annette Marleau, Ph.D., is Chief Scientific Officer at Sigyn Therapeutics. Prior to joining the company, she was Chief Technology Officer at Immunicom Inc. and Director of Research at Aethlon Medical Inc. Additionally, she is an inventor on pending and issued patents underlying blood purification therapies targeting cancer, inflammatory disorders and life-threatening infectious diseases. She holds a Ph.D. from Western University, an M.S. from the University of Guelph and a B.S. from the University of Waterloo in Canada.

Jerry DeCiccio, CPA, is CFO at Sigyn Therapeutics. He has more than 40 years of financial industry experience. Previously, he was CFO/COO at Intech Electromechanical, CFO/COO at GTC Telecom, CFO at Incomnet Communications and President at Cerebain Biotech Corp. He also served in senior financial roles at Parker Hannifin Corp., Waste Management Inc. and Newport Corp. He earned a bachelor’s degree in accounting and business administration from Loma Linda University and an MBA in finance and systems technology from the University of Southern California.

Sigyn Therapeutics Inc. (OTCQB: SIGY), closed Wednesday's trading session at $4.5, even for the day, on 37 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.08/$12.80.

Recent News

• Sigyn Therapeutics Inc. (OTCQB: SIGY) - BioMedNewsBreaks - Sigyn Therapeutics Inc. (SIGY) Making Drugs Perform Better
• BioMedNewsBreaks - Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges
• BioMedNewsBreaks - Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

SOBRsafe Inc. (NASDAQ: SOBR)

The QualityStocks Daily Newsletter would like to spotlightFathom SOBRsafe Inc. (NASDAQ: SOBR).

SOBRSafe (NASDAQ: SOBR), providers of next-generation transdermal alcohol-detection solutions, is hosting the first segment of its new behavioral-health webinar series. Titled "The Future of Alcohol Monitoring Is Here: Discover Touch-Based Detection with SOBRsafe," the webinar begins today at 3 p.m. ET. The webinar is hosted by recovery advocate and TV personality Jason Wahler and features experts in the field, including Keenen Diamond, president and COO of Oceanfront Recovery; Wendy Stine, a certified interventionist and addictions counselor; and Matt Mitchell, transdermal technology veteran and director of partnerships for SOBRsafe.

To register for the webinar, visit https://ibn.fm/MdgTr

To view the full press release, visit https://ibn.fm/Jeb3j

SOBRsafe Inc. (NASDAQ: SOBR) is a provider of a game-changing transdermal (touch-based) alcohol detection technology that can improve workplace safety and provides advanced screening and monitoring solutions for the behavioral health industry.

Alcohol misuse is the fourth leading cause of preventable death in the U.S., and the seventh worldwide. Nearly half of all industrial accidents with injuries are alcohol-related, and 1-in-10 U.S. commercial drivers tests positive for alcohol – the highest rate in the world. Despite these statistics, prevention and monitoring solutions have not kept pace with this epidemic. Legacy detection technologies are invasive and inefficient, unhygienic and unconnected. SOBRsafe believes there is a better way.

The company has developed a patent-pending alcohol detection device called SOBRcheck™ for use in detecting alcohol in humans, with just the touch of a finger. SOBRsafe’s next-generation transdermal technology detects and instantaneously reports the presence of alcohol as emitted through a user’s skin. No breath, blood or urine sample is required. SOBRsafe believes its technology is a superior, hygienic alternative to traditional breathalyzers for frontline, preventative applications.

With a powerful backend data platform, SOBRsafe provides humane, passive and connected alcohol detection for the behavioral health, transportation, oil and gas, judicial and consumer markets.

A preventative solution in historically reactive industries, SOBRsafe technology is being deployed for commercial fleets, workplaces, alcohol rehabilitation, probation management and teen drivers. This monitoring technology helps prevent intoxicated workers from taking the factory floor or drivers from receiving the keys to a truck, bus or family car. An offender is immediately flagged, and an administrator is empowered to take the appropriate corrective actions.

SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure™) and licensing or white labeling.

The company is headquartered in the Denver (CO) Technology Center.

Products

The SOBRsafe technology is integrated within the company’s robust and scalable data platform, producing statistical and measurable user and business data.

SOBRsafe™

With a mission is to save lives, increase productivity, create significant economic benefits and positively impact behavior, SOBRsafe developed the scalable, patent-pending SOBRsafe™ platform for non-invasive alcohol detection, real-time reporting and historical data aggregation.

SOBRsafe is a solution that has broad applications in behavioral health, fleet and facility safety, youth drivers and judicial markets.

SOBRcheck™

SOBRcheck is the company’s stationary identification and alcohol monitoring product, providing a quick, specific-point-in-time test for the presence of alcohol. In hygienic, real-time fashion, SOBRcheck verifies user identity and determines the absence or presence of alcohol.

SOBRcheck provides an administrator immediate results – delivered securely – to aid in the efficient management of an existing substance abuse policy.

SOBRsure™

SOBRsure is the company’s transdermal, alcohol-detecting wearable. SOBRsure provides continuous, mobile alcohol monitoring. The band’s advanced alcohol safety technology discreetly detects and instantaneously reports the presence of alcohol in the body. Additionally, SOBRsure provides app-based alcohol detection alerts, pinpoint location tracking and band-removal notifications.

The SOBRcheck and SOBRsure revenue models consist of two components: (1) a hardware device purchase and (2) a recurring monthly SaaS subscription fee.

Design, manufacturing, quality testing and distribution for all SOBRsafe devices takes place in the U.S.

 

Market Opportunity

A report from Data Bridge Market Research, an international market research and consulting firm, estimated the global alcohol sensor market at $2.3 billion in 2022. The market is forecast to reach a value of $6.3 billion by 2030, recording a CAGR of 13.7% over the forecast period.

Market growth drivers, as cited by the report, include rising alcohol consumption rates, more stringent laws pertaining to alcohol consumption and new, more effective technologies that facilitate detection and enforcement.

Greater awareness of alcohol consumption as a potential threat to public and workplace safety has led to increased emphasis on preventing operation of motor vehicles and machinery by those under the influence of alcohol and promoting responsible alcohol consumption, as the report details.

Management Team

David Gandini is Chairman and CEO of SOBRsafe. He most recently served as president of IPS Denver, a bank card personalization company. Prior to that, Dave was the COO at First World Communications, a U.S. internet and data center provider, and participated in its successful IPO. He previously founded Pace Network Services and facilitated a successful exit to ICG Communications. Dave also co-founded Detroit-based Digital Signal in the fiber optic long haul market sector, where he executed a successful exit to SP Telecom.

Chris Whitaker, CPA, is CFO of SOBRsafe. Previously, Chris had served as the Company’s Vice President of Finance and Accounting. He has held various executive finance positions with large public multi-national corporations and small entrepreneurial companies throughout a progressive 30-year career that began with KPMG. Chris was formerly President – Americas and Vice President of Finance and Administration for public, multinational corporation Elixinol. He also served as the Managing Director of AEGIS Financial Consulting, leading a team of consultants in providing fractional CFO and financial consulting services to a wide variety of businesses in the public and private sectors.

Scott Bennett is EVP, Business Operations at SOBRsafe. He has more than 20 years of experience as a senior executive in technology-driven enterprises. Prior to joining SOBRsafe, he co-founded cybersecurity firm GBprotect and served as its COO until its successful sale to Nuspire. He previously served as Chief Technical Officer/Chief Information Security Officer of fintech businesses Catalyst Card Company and Integrated Printing Solutions.

SOBRsafe Inc. (NASDAQ: SOBR), closed Wednesday's trading session at $0.5, up 16.6317%, on 1,018,263 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.2004/$2.53.

Recent News

• SOBRsafe Inc. (NASDAQ: SOBR) - InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Kicks Off First in Behavioral Health Webinar Series Today, Register Now
• InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Expands to Psychological Services and Therapy Sector
• InvestorNewsBreaks - SOBR Safe Inc. (NASDAQ: SOBR) Announces Webinar Series Focused on Behavioral Health, First Segment Scheduled for March 27

Starco Brands Inc. (OTCQB: STCB)

The QualityStocks Daily Newsletter would like to spotlight Starco Brands Inc. (OTCQB: STCB).

Starco Brands Inc. (OTCQB: STCB) is a modern-day invention factory. The company’s unwavering mission is to invent and acquire consumer products and brands with behavior-changing technologies that spark excitement in the everyday.

This consumer product company has grown from a few million dollars in revenue to a current run rate of approximately $67 million in annual revenue in one year.

The company has succeeded by identifying whitespaces in eight core consumer categories and then either: 1) leveraging its internal R&D capabilities and dedicated manufacturing network to invent new technologies and brands or 2) utilizing the management team’s extensive M&A experience to acquire brands that fill the industry void, delighting consumers and retailers alike.

Whether the brand is developed internally or acquired, the company employs a modern marketing playbook to ensure its brands are at the forefront of culture; garnering unprecedented media attention and engagement that supports a robust sales network.

Starco Brands’ core competencies are inventing technologies, acquiring companies, marketing, building trends, pushing awareness, penetrating media (social and otherwise) and executing cutting edge pull-through strategies with a roster of globally recognized celebrities, influencers and media and distribution partners.

A commitment to changing the way people approach everyday activities is innate in the company’s corporate DNA.

The company is based in Santa Monica, California.

Brands

Whereas other consumer products companies are content with evolution, Starco Brands has its mind set on creating a revolution across the industry. From disrupting the spirits industry with Whipshots, the world’s only vodka-infused whipped cream, to Soylent, the original food tech company, Starco Brands is putting the CPG world on notice. Its portfolio of brands includes:

• Whipshots is a first-of-its-kind alcoholic whipped cream launched in 2021 with celebrity partner Cardi B. Consumers have embraced this boozy concoction, putting it on top of cocktails, coffees and desserts, or enjoying it straight from the can. In just over a year, the brand has sold over 2 MILLION cans, making it one of the fastest growing spirits in history.
• Winona Pure gives consumers movie theatre popcorn in the comfort of their own homes. All the flavor and none of the additives is the story behind these all-natural, non-GMO popcorn seasoning sprays. A simple spray is all it takes to add the perfect pop of flavor to the classic theatre treat.
• Art of Sport, co-founded by the great Kobe Bryant, is the number one body care brand for athletes. With a growing line of personal care products tested by the world’s greatest athletes, these daily skin essentials give consumers everything they need to feel fresh, stay protected and confident and perform at their peak every day.
• Skylar is the first and only line of perfumes on the market that are hypoallergenic and safe for sensitive skin. With the strong support of industry titan Sephora, the brand has quickly attracted a loyal following.
• Soylent is a technological feat. Originally funded by Google Ventures and Andreessen Horwitz, Soylent is dubbed as the world’s most perfect food. Made from sustainably grown plant-based ingredients, Soylent’s line of products is scientifically developed to provide all the functional ingredients, vitamins, minerals, fats, carbohydrates and protein that the body needs – all in convenient, delicious and affordable packages. Soylent’s innovative product line-up includes complete nutrition powders, ready-to-drink shakes, 100-calorie snack bars, high protein nutrition shakes and energy boosting nutrition shakes. Soylent was also the recipient of the 2023 Product of the Year Award by Kantar, a global leader in consumer research.

With award-winning marketing talent, Starco Brands develops robust, integrated marketing plans for every brand in its portfolio, ensuring an impactful presence across all verticals.

Market Outlook

Starco Brands’ varied brand portfolio gives it access to the growth of numerous product categories that are ripe for innovation.

Through its February 2023 acquisition of complete nutrition pioneer Soylent, Starco Brands is positioned to capitalize on the projected growth of the plant-based nutrition space. Research firm Statista valued the plant-based nutrition market at $29.4 billion in 2020 and forecasts its value at nearly $162 billion by 2030, representing a CAGR of 18.7% for the period.

Likewise, Starco Brands gained improved access to the global fragrance market through its December 2022 acquisition of Skylar. According to a report by Grand View Research, the global perfume market was valued at $50.85 billion in 2022 and is expected to grow to a value of nearly $80 billion by 2030, achieving a CAGR of 5.9% over the forecast period.

The company is primed to expand its access to other growth verticals as it advances on its path to invent and acquire behavior-changing technologies and brands.

Management Team

Ross Sklar is the CEO of Starco Brands. A chemical formulator by trade, he started his first company while still in college. Since 2004, he has made over a dozen acquisitions with multiple exits and controls an eclectic collection of industrial, household, personal care and food and beverage manufacturers covering many consumer-packaged goods categories.

Darin Brown is the Chief Operating Officer of Starco Brands. With over 20 years of experience in chemical manufacturing, business development, finance and mergers and acquisitions, he has scaled the company from the ground up. He oversees all internal operations for Starco Brands and is an integral liaison between the company and Mr. Sklar’s manufacturing facilities.

David Dreyer is Chief Marketing Officer of Starco Brands. With over 25 years of experience working with blue chip and startup brands, he oversees all marketing initiatives for the company. Mr. Dreyer comes to Starco having worked with such standout brands as Apple, Pepsi, Pizza Hut, Dr Pepper, Snapple, Infiniti, The GRAMMY’s, Honda and Stamps.com. He is also a Professor of Advertising at USC’s Annenberg School for Communication.

Starco Brands Inc. (STCB), closed Wednesday's trading session at $0.122, even for the day, on 11,860 volume. The average volume for the last 3 months is 32,683 and the stock's 52-week low/high is $0.115/$0.20.

Recent News

• Starco Brands Inc. (OTCQB: STCB) - Whipshots® by Starco Brands Shatters Expectations with Explosive Growth and Nationwide Expansion
• Starco Brands Celebrates Unprecedented Organic Growth of Winona Pure® Popcorn Spray
• Starco Brands Partners with B2i Digital to Enhance Shareholder Communication

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF)

The QualityStocks Daily Newsletter would like to spotlight Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF).

Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) is a mineral exploration company engaged in advancing precious and base metal deposits in the state of Arizona. Its flagship copper-gold-zinc-silver asset is the Kay Mine Project, located in Yavapai County. The company also owns Sugarloaf Peak gold project in La Paz County.

The company in October 2022 received permit approval from the Bureau of Land Management (BLM) for two new drill pads, located approximately 1,200 meters west of the Kay Mine Deposit. These new pads will allow for testing of the company’s Western Target, while also allowing for drilling of additional coincident anomalies located between the Central and Western Targets. Construction of the drill road for the Central Target (located 500 meters west of the Kay Mine Deposit) is currently underway, with drilling expected to begin in November 2022. Road construction for the Western Target will begin upon confirmation of BLM acceptance of the company’s posted bond, with drilling expected to commence in Q1 2023.

The company is fully funded, with $60 million in cash as of June 30, 2022, to complete the remaining 18,000 meters planned for the Phase 2 program at Kay, as well as an additional 76,000 meters in the Phase 3 program (budgeted at $27 million), which will be used to test the numerous parallel targets heading west of the Kay Deposit, as well as the northern and southern extensions of the Kay Deposit.

Arizona Metals Corp. is based in Toronto, Canada.

Projects

Arizona Metals Corp. owns 100% of the Kay Mine property in Yavapai County, which is located on a combination of patented and BLM claims totaling 1,300 acres that are not subject to any royalties. An historic estimate by Exxon Minerals in 1982 reported a “proven and probable reserve of 6.4 million short tons at a grade of 2.2% copper, 2.8 grams per ton gold, 3.03% zinc, and 55 grams per ton silver.” The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported by Exxon, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a “qualified person” (as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects) before the historic estimate can be verified and upgraded to be a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

The company also owns 100% of the Sugarloaf Peak Property in La Paz County, which is located on 4,400 acres of BLM claims. Sugarloaf is a heap-leach, open-pit target and has a historic estimate of “100 million tons containing 1.5 million ounces (of) gold” at a grade of 0.5 grams per ton. The historic estimate at the Sugarloaf Peak Property was reported by Westworld Resources in 1983. The historic estimate has not been verified as a current mineral resource. None of the key assumptions, parameters, and methods used to prepare the historic estimate were reported, and no resource categories were used. Significant data compilation, re-drilling and data verification may be required by a qualified person before the historic estimate can be verified and upgraded to a current mineral resource. A qualified person has not done sufficient work to classify it as a current mineral resource, and Arizona Metals is not treating the historic estimate as a current mineral resource.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, reports that global demand for gold during the first six months of 2022 was 2,189 tons, a 12% increase in demand over the same period in 2021. Demand came primarily from gold bar and coin investors, jewelry consumers, central bank purchases to bolster currency reserves and technology manufacturing.

The average price per ounce for the period was $1,871, marking a 1% year-over-year increase. The council reported gold mine production for the period was up 3% over 2021 at 1,764 tons. For the remainder of 2022 and into 2023, the council projects flat gold demand with possible slight increases in gold mine production. The council notes that unpredictable geopolitical factors, the Ukraine war for example, and likelihood of global economic slowdown could have significant near-term impact on gold demand and prices.

Management Team

Marc Pais is President and CEO of Arizona Metals. He previously founded and served as President of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. He has seven years of experience as a Mining Analyst, with a focus on precious metals development companies. He holds a B.Sc. in Geological Engineering (Mineral Exploration) from Queen’s University in Canada.

David Smith is the Vice President, Exploration of Arizona Metals. He has 30 years of global precious metals exploration experience, including codiscovery of the Solidaridad/La Sabila deposit in Mexico with deposits estimated at 1 million ounces of gold. His core areas of expertise are managing mineral projects from acquisition to exploration, resource modeling and mineral project development. He holds an M.Sc. from the University of Oregon and an MBA from Pinchot University/Presidio Graduate School.

Paul Reid is the Executive Chairman of Arizona Metals. He previously founded and served as Executive Chairman of Telegraph Gold (listed as Castle Mountain Mining), which was acquired by Equinox Gold, a TSX-listed mining company. Paul has extensive experience as an Investment Banking professional, involved in raising capital, go-public transactions, and advisory services.

Arizona Metals Corp. (OTCQX: AZMCF), closed Wednesday's trading session at $1.4057, up 2.4936%, on 105,132 volume. The average volume for the last 3 months is 120,767 and the stock's 52-week low/high is $1.21/$3.40.

Recent News

• Arizona Metals Corp. (TSX: AMC) (OTCQX: AZMCF) - Looming Supply Deficit Could Make Copper Outperform Gold in 2024
• Arizona Metals Corp Identifies New Priority Drill Targets at its Kay Mine Project
• Arizona Metals Corp Completes Acquisition of Additional Private Lands at its Kay Mine Project

OK Stone Engineering Inc.

The QualityStocks Daily Newsletter would like to spotlight OK Stone Engineering Inc.

OK Stone Engineering Inc. is a Texas-based company formed to manufacture engineered quartz slabs to be used as materials for countertops and tile in the building and construction industry. The company’s manufacturing process uses next-generation technologies which reduce costs, improve the quality of the finished product and increase safety of workers in the manufacturing process.

OK Stone is the first high tech source of U.S.-made quartz stone products. The company, with joint venture partner Breton S.p.A., has announced a new factory for engineered stone in Fort Worth, Texas, to fill the massive supply gap in the U.S. market, where the domestic shortage is projected to increase to 140 million square feet annually by 2026. Construction of the facility is scheduled to begin in 2024, with production projected to start in mid to late 2025 and the is facility projected to be scaling to full production in early 2026.

The factory will be the first in the U.S. to employ Breton’s Bioquartz® technology, a transformative state-of-the-art manufacturing process. There are only nine engineered stone slab manufacturers in the U.S., and seven of those are based on older Breton technology. Only OK Stone is investing in this latest technology while other manufacturing facilities risk falling behind.

Products

OK Stone’s licensed Bioquartz® manufacturing technology, which has been under development for a decade, will provide a significant competitive advantage in the market by solving the most frustrating problems faced by customers. Breton, based in Italy, is the definitive international leader in designing and developing engineered stone production plants, with more than 95% of global market share.

This next-gen manufacturing technology will allow OK Stone to source a more reliable and less expensive supply of domestic raw materials, replacing variable supplies from Asia. It also reduces costs by more than 10% while producing quartz slabs with an unlimited range of aesthetic effects that older manufacturing technologies cannot replicate.

Importantly, the Bioquartz® process eliminates the risk that workers can develop silicosis, an incurable lung disease caused by inhaling crystalline silica particles. Expected new government regulations to prevent silicosis are likely to impact other U.S. manufacturers. The company’s expected regulatory compliance, as well as its avoidance of international shipping costs for raw materials – which have been unstable since 2021 – are among the factors likely to provide OK Stone with major competitive advantages in the market.

The company will sell its factory output through the existing network of stone distributors that supply the building and construction industry.

Market Opportunity

According to a report by Allied Market Research, a research, consulting and advisory firm, the global engineered stone market was valued at $21.1 billion in 2021 and is projected to reach $35.1 billion by 2031, growing at a CAGR of greater than 5% for the forecast period.

Engineered stone is used in a number of applications in the construction industry, including countertops, flooring and wall tiles, fireplaces and more. The report states that rapid expansion in construction is boosting the global demand for engineered stone.

Management Team

OK Stone’s management team recently designed, built and operated a Breton factory with more than $100 million in annual revenues.

The CEO of OK Stone has almost two decades of experience in the engineered stone industry. He began as a production engineer, later hired as a factory manager and eventually in the role of Managing Partner an an Industrial Investment fund, focusing on investments in engineered stone. He holds a Mechanical Engineering degree and an MBA.

The Chief Marketing Officer at OK Stone has more than 15 years of experience as a sales and marketing executive in the industry. He has worked for the top tier of engineered surfaces companies as well as a significant U.S.-based engineered stone company. He has recently been Sales and Marketing Director of a fully scaled Breton equipped factory, and was previously part of the founding team at a separate Breton factory, where he worked extensively in the U.S. market.

Ronald Max is COO at OK Stone. He has more than 35 years of experience in operations and finance. He has been involved in over $4 billion in real estate transactions and has extensive expertise in complicated ownership structures such as sale-leaseback financing, ground lease bifurcations and real estate securities offerings. In addition, he has experience in creating operating budgets, financial management and industrial real estate development for highly scaled enterprises.

Recent News

• OK Stone Engineering Inc. - OK Stone Engineering Inc. Company Profile
• OK Stone Engineering Inc. Company Profile
• OK Stone Engineering Inc. Company Profile